Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's novel, proprietary technology enhances radiotherapy energy with the goal of providing a new, more efficient treatment for cancer patients.
Products are compatible with current radiotherapy treatments and aim to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia-Pacific region.
In January 2019, Nanobiotix signed a collaboration with the MD Anderson Cancer Center for 9 clinicals trials in six cancers types (head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers). The first trials are to be launched in 2019.
In April 2019, Nanobiotix received its first European market approval enabling the commercialization of its product, Hensify®, in locally advanced soft tissue sarcoma.